Diabetic renal disease

An overview with therapeutic implications

Jiten P. Vora, Sharon Anderson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In the United States, diabetic nephropathy is now the leading cause of end-stage renal disease (ESRD) leading to kidney transplant. In insulin-dependent diabetes mellitus (IDDM), the evolution of renal disease follows five characteristic stages: glomerular hyperfiltration and nephromegaly are observed at the time of diagnosis (stage 1). This is followed by a clinically silent phase of developing structural injury (stage 2). “Incipient” diabetic nephropathy follows with microalbuminuria (stage 3). Overt nephropathy (stage 4) leads to ESRD (stage 5). Much less is known about renal disease in patients with non-insulin-dependent diabetes mellitus. Recent studies, however, indicate that the process is functionally and structurally analogous to that in IDDM. Experimental and clinical studies have improved our understanding of the pathophysiology of diabetic renal disease. The most promising interventions appear to be optimal glycemic control, dietary protein restriction, and antihypertensive therapy. Efficacy varies with stage of disease. Current evidence suggests that during stages 1 and 2 the rate of progression of microalbuminuria and the decline in glomerular filtration rate can be reduced by maintaining near-normoglycemia and, possibly, with angiotensin-converting enzyme inhibitor (CEI) administration. Following the appearance of persistent protein-uria, progression to ESRD can be delayed by aggressive antihypertensive therapy and restriction of dietary protein intake. Recent studies suggest that CEI may be better than other antihypertensive agents. Therapies have been identified that can slow the progression of diabetic renal disease and delay the appearance of ESRD.

Original languageEnglish (US)
Pages (from-to)223-230
Number of pages8
JournalEndocrinologist
Volume2
Issue number4
StatePublished - 1992

Fingerprint

Chronic Kidney Failure
Kidney
Antihypertensive Agents
Dietary Proteins
Diabetic Nephropathies
Type 1 Diabetes Mellitus
Therapeutics
Enzyme Inhibitors
Glomerular Filtration Rate
Angiotensin-Converting Enzyme Inhibitors
Type 2 Diabetes Mellitus
Transplants
Wounds and Injuries
Proteins

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Diabetic renal disease : An overview with therapeutic implications. / Vora, Jiten P.; Anderson, Sharon.

In: Endocrinologist, Vol. 2, No. 4, 1992, p. 223-230.

Research output: Contribution to journalArticle

@article{7d28912cb9db4380b0c3c2652116102f,
title = "Diabetic renal disease: An overview with therapeutic implications",
abstract = "In the United States, diabetic nephropathy is now the leading cause of end-stage renal disease (ESRD) leading to kidney transplant. In insulin-dependent diabetes mellitus (IDDM), the evolution of renal disease follows five characteristic stages: glomerular hyperfiltration and nephromegaly are observed at the time of diagnosis (stage 1). This is followed by a clinically silent phase of developing structural injury (stage 2). “Incipient” diabetic nephropathy follows with microalbuminuria (stage 3). Overt nephropathy (stage 4) leads to ESRD (stage 5). Much less is known about renal disease in patients with non-insulin-dependent diabetes mellitus. Recent studies, however, indicate that the process is functionally and structurally analogous to that in IDDM. Experimental and clinical studies have improved our understanding of the pathophysiology of diabetic renal disease. The most promising interventions appear to be optimal glycemic control, dietary protein restriction, and antihypertensive therapy. Efficacy varies with stage of disease. Current evidence suggests that during stages 1 and 2 the rate of progression of microalbuminuria and the decline in glomerular filtration rate can be reduced by maintaining near-normoglycemia and, possibly, with angiotensin-converting enzyme inhibitor (CEI) administration. Following the appearance of persistent protein-uria, progression to ESRD can be delayed by aggressive antihypertensive therapy and restriction of dietary protein intake. Recent studies suggest that CEI may be better than other antihypertensive agents. Therapies have been identified that can slow the progression of diabetic renal disease and delay the appearance of ESRD.",
author = "Vora, {Jiten P.} and Sharon Anderson",
year = "1992",
language = "English (US)",
volume = "2",
pages = "223--230",
journal = "Endocrinologist",
issn = "1051-2144",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Diabetic renal disease

T2 - An overview with therapeutic implications

AU - Vora, Jiten P.

AU - Anderson, Sharon

PY - 1992

Y1 - 1992

N2 - In the United States, diabetic nephropathy is now the leading cause of end-stage renal disease (ESRD) leading to kidney transplant. In insulin-dependent diabetes mellitus (IDDM), the evolution of renal disease follows five characteristic stages: glomerular hyperfiltration and nephromegaly are observed at the time of diagnosis (stage 1). This is followed by a clinically silent phase of developing structural injury (stage 2). “Incipient” diabetic nephropathy follows with microalbuminuria (stage 3). Overt nephropathy (stage 4) leads to ESRD (stage 5). Much less is known about renal disease in patients with non-insulin-dependent diabetes mellitus. Recent studies, however, indicate that the process is functionally and structurally analogous to that in IDDM. Experimental and clinical studies have improved our understanding of the pathophysiology of diabetic renal disease. The most promising interventions appear to be optimal glycemic control, dietary protein restriction, and antihypertensive therapy. Efficacy varies with stage of disease. Current evidence suggests that during stages 1 and 2 the rate of progression of microalbuminuria and the decline in glomerular filtration rate can be reduced by maintaining near-normoglycemia and, possibly, with angiotensin-converting enzyme inhibitor (CEI) administration. Following the appearance of persistent protein-uria, progression to ESRD can be delayed by aggressive antihypertensive therapy and restriction of dietary protein intake. Recent studies suggest that CEI may be better than other antihypertensive agents. Therapies have been identified that can slow the progression of diabetic renal disease and delay the appearance of ESRD.

AB - In the United States, diabetic nephropathy is now the leading cause of end-stage renal disease (ESRD) leading to kidney transplant. In insulin-dependent diabetes mellitus (IDDM), the evolution of renal disease follows five characteristic stages: glomerular hyperfiltration and nephromegaly are observed at the time of diagnosis (stage 1). This is followed by a clinically silent phase of developing structural injury (stage 2). “Incipient” diabetic nephropathy follows with microalbuminuria (stage 3). Overt nephropathy (stage 4) leads to ESRD (stage 5). Much less is known about renal disease in patients with non-insulin-dependent diabetes mellitus. Recent studies, however, indicate that the process is functionally and structurally analogous to that in IDDM. Experimental and clinical studies have improved our understanding of the pathophysiology of diabetic renal disease. The most promising interventions appear to be optimal glycemic control, dietary protein restriction, and antihypertensive therapy. Efficacy varies with stage of disease. Current evidence suggests that during stages 1 and 2 the rate of progression of microalbuminuria and the decline in glomerular filtration rate can be reduced by maintaining near-normoglycemia and, possibly, with angiotensin-converting enzyme inhibitor (CEI) administration. Following the appearance of persistent protein-uria, progression to ESRD can be delayed by aggressive antihypertensive therapy and restriction of dietary protein intake. Recent studies suggest that CEI may be better than other antihypertensive agents. Therapies have been identified that can slow the progression of diabetic renal disease and delay the appearance of ESRD.

UR - http://www.scopus.com/inward/record.url?scp=84901955878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901955878&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 223

EP - 230

JO - Endocrinologist

JF - Endocrinologist

SN - 1051-2144

IS - 4

ER -